Acclarent
| Company type | Subsidiary |
|---|---|
| Industry | Medical devices |
| Founded | 2004 |
| Founder | Joshua Makower |
| Headquarters | Menlo Park, California , United States |
Area served | Over 45 countries |
Key people | Joshua Makower (Chairman of the Board), Jeff Hopkins (President) |
| Products | Relieva Balloon Sinuplasty system, Relieva Ultirra sinus balloon catheters, Relieva Luma sinus illumination guidewires, Relieva Vortex, Cyclops articulating endoscope, Aera balloon device |
Number of employees | 300+ |
| Parent | Integra LifeSciences |
| Website | www |
Acclarent, Inc. originated as a privately owned, venture-funded enterprise and currently functions as a subsidiary under Integra LifeSciences. Headquartered in Irvine, within Orange County, California, the company specializes in developing technologies addressing ENT (Ear, Nose, and Throat) conditions.
History
Established in 2004, Acclarent employs over 300 personnel and has a presence in upwards of 45 countries. Its main corporate office is situated in Menlo Park, California.
From its founding, the company secured more than $103.5 million in funding from venture capital firms such as New Enterprise Associates (NEA), Versant Ventures, Delphi Ventures, Meritech Capital Partners, and Johnson & Johnson Development Corporation.
The founder of Acclarent is Joshua Makower, who continues to hold the position of Chairman of the Board. Between 2004 and 2012, William M. Facteau served as President and COO; the current president is Jeff Hopkins.
In May 2005, the company obtained FDA approval for its Relieva Balloon Sinuplasty system. Its product lineup features over 40 FDA-cleared devices including Relieva Ultirra sinus balloon catheters, Relieva Luma sinus illumination guidewires, Relieva Vortex for targeted intra-sinus fluid delivery, and the Cyclops articulating endoscope.
Acclarent was acquired by Ethicon Inc., a subsidiary of Johnson & Johnson, in January 2010. Later, in September 2017, it gained FDA clearance for the Aera balloon device—the first approved treatment for chronic eustachian tube dysfunction.
In December 2023, Integra LifeSciences announced plans to purchase Acclarent for $275 million, with the acquisition finalized on April 1, 2024.